The record first. On January 2, 2024, International Business Machines Corporation was granted US11860584B2, "Dynamically controllable smartwatch" (CPC G06N 20/00 and G16H 40/63). The named inventor is Sarbajit K. Rakshit. The claim covers a smartwatch whose behavior adapts via machine learning — on-device intelligence applied to a wearable.
Follow the assignee strategy. IBM is not a consumer-smartwatch maker; a smartwatch grant in its name is a portfolio asset, not a product roadmap. Enterprise IP holders accumulate claims in adjacent consumer categories precisely so they can license, cross-license, or assert them. The business model is the patent itself, monetized through licensing rather than hardware.
The business framing is portfolio-as-revenue. For a firm whose strategy includes IP licensing, a granted patent in a fast-growing category like wearable AI is a long bet on future licensing leverage. The R&D is priced today against licensing revenue or defensive value realized later — an option, not a shipping plan.
Comparability discipline applies. "Smartwatch AI" patents from a device maker imply a product; from an IP-licensing enterprise they imply a portfolio play. The assignee distinguishes them. The filing pins this claim to a non-maker assignee — useful for reading commercialization intent, and a signal a product-centric reading would miss.
What the document does not disclose is the economics. It is a method claim, not a licensing figure. It will not tell you licensing revenue, assertion plans, or portfolio value. The grant establishes a licensable position; the financials are undisclosed.
For investors, the throughline is this: not every device patent implies a device — some are portfolio bets monetized through licensing, and the assignee field tells you which is which.